Brian Walitt1, Tory P Johnson2. 1. National Institute of Neurological Disorders and Stroke. 2. Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: The coronavirus disease 2019 (COVID) pandemic has resulted in significant mortality and morbidity globally. Patients who survive infection may develop continuing disease collectively known as the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC), which includes neurologic symptoms especially fatigue and cognitive impairment. The pathogenic mechanisms driving PASC are unknown although a postinfectious process, persistent infection, or lasting pathophysiological changes that occur during acute infection are all suspected to contribute. RECENT FINDINGS: Here we review the current evidence underlying potential pathogenic mechanisms of the neurological complications of PASC with particular emphasis on the evidence for postinfectious immune processes and viral persistence. SUMMARY: Immune dysregulation favoring persistent inflammation, including neuroinflammation and enhanced autoimmunity, are present in patients with COVID and likely contribute to the development of PASC. Limited evidence of viral persistence exists but may explain the ongoing inflammatory processes and affinity maturation observed in some patients recovering from COVID infections. No specific studies to date have tied persistent infection to PASC. CNS trauma, in particular hypoxic changes in the CNS, and psychiatric complications occur with greater frequency in patients with COVID and may contribute to the development of PASC. Future research is needed to fully understand the pathophysiological mechanisms driving PASC.
PURPOSE OF REVIEW: The coronavirus disease 2019 (COVID) pandemic has resulted in significant mortality and morbidity globally. Patients who survive infection may develop continuing disease collectively known as the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC), which includes neurologic symptoms especially fatigue and cognitive impairment. The pathogenic mechanisms driving PASC are unknown although a postinfectious process, persistent infection, or lasting pathophysiological changes that occur during acute infection are all suspected to contribute. RECENT FINDINGS: Here we review the current evidence underlying potential pathogenic mechanisms of the neurological complications of PASC with particular emphasis on the evidence for postinfectious immune processes and viral persistence. SUMMARY: Immune dysregulation favoring persistent inflammation, including neuroinflammation and enhanced autoimmunity, are present in patients with COVID and likely contribute to the development of PASC. Limited evidence of viral persistence exists but may explain the ongoing inflammatory processes and affinity maturation observed in some patients recovering from COVID infections. No specific studies to date have tied persistent infection to PASC. CNS trauma, in particular hypoxic changes in the CNS, and psychiatric complications occur with greater frequency in patients with COVID and may contribute to the development of PASC. Future research is needed to fully understand the pathophysiological mechanisms driving PASC.
Authors: Cecilia L H Xu; Manjri Raval; Jesse A Schnall; Jason C Kwong; Natasha E Holmes Journal: Pediatr Infect Dis J Date: 2020-09 Impact factor: 2.129
Authors: Alexander E Merkler; Neal S Parikh; Saad Mir; Ajay Gupta; Hooman Kamel; Eaton Lin; Joshua Lantos; Edward J Schenck; Parag Goyal; Samuel S Bruce; Joshua Kahan; Kelsey N Lansdale; Natalie M LeMoss; Santosh B Murthy; Philip E Stieg; Matthew E Fink; Costantino Iadecola; Alan Z Segal; Marika Cusick; Thomas R Campion; Ivan Diaz; Cenai Zhang; Babak B Navi Journal: JAMA Neurol Date: 2020-07-02 Impact factor: 18.302
Authors: Saul A Villeda; Jian Luo; Kira I Mosher; Bende Zou; Markus Britschgi; Gregor Bieri; Trisha M Stan; Nina Fainberg; Zhaoqing Ding; Alexander Eggel; Kurt M Lucin; Eva Czirr; Jeong-Soo Park; Sebastien Couillard-Després; Ludwig Aigner; Ge Li; Elaine R Peskind; Jeffrey A Kaye; Joseph F Quinn; Douglas R Galasko; Xinmin S Xie; Thomas A Rando; Tony Wyss-Coray Journal: Nature Date: 2011-08-31 Impact factor: 49.962
Authors: Elisabeth B Marsh; Christian Brodbeck; Rafael H Llinas; Dania Mallick; Joshua P Kulasingham; Jonathan Z Simon; Rodolfo R Llinás Journal: Proc Natl Acad Sci U S A Date: 2020-12-14 Impact factor: 11.205
Authors: Jeroen J A van Kampen; David A M C van de Vijver; Pieter L A Fraaij; Bart L Haagmans; Mart M Lamers; Nisreen Okba; Johannes P C van den Akker; Henrik Endeman; Diederik A M P J Gommers; Jan J Cornelissen; Rogier A S Hoek; Menno M van der Eerden; Dennis A Hesselink; Herold J Metselaar; Annelies Verbon; Jurriaan E M de Steenwinkel; Georgina I Aron; Eric C M van Gorp; Sander van Boheemen; Jolanda C Voermans; Charles A B Boucher; Richard Molenkamp; Marion P G Koopmans; Corine Geurtsvankessel; Annemiek A van der Eijk Journal: Nat Commun Date: 2021-01-11 Impact factor: 14.919
Authors: Laith J Abu-Raddad; Hiam Chemaitelly; Joel A Malek; Ayeda A Ahmed; Yasmin A Mohamoud; Shameem Younuskunju; Zaina Al Kanaani; Abdullatif Al Khal; Einas Al Kuwari; Adeel A Butt; Peter Coyle; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Hadi M Yassine; Mohamed G Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Roberto Bertollini Journal: Infect Genet Evol Date: 2020-12-24 Impact factor: 3.342
Authors: Marc Emmenegger; Sreedhar Saseendran Kumar; Vishalini Emmenegger; Tomas Malinauskas; Thomas Buettner; Laura Rose; Peter Schierack; Martin F Sprinzl; Clemens J Sommer; Karl J Lackner; Adriano Aguzzi; Dirk Roggenbuck; Katrin B M Frauenknecht Journal: PLoS Pathog Date: 2021-12-03 Impact factor: 6.823
Authors: Hannah E Davis; Gina S Assaf; Lisa McCorkell; Hannah Wei; Ryan J Low; Yochai Re'em; Signe Redfield; Jared P Austin; Athena Akrami Journal: EClinicalMedicine Date: 2021-07-15